IMUX News and Press, Immunic Inc. From 01/05/24

Immunic Highlights 2023 Accomplishments and Upcoming Milestones PR Newswire – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis , Consistent Across the Entire Progressive Multiple Sclerosis Population and All S...

Immunic, Inc. Announces Private Placement of up to $240 Million PR Newswire NEW YORK , Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, s...

2023-11-22 16:27:08 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic For fu...

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis PR Newswire – Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond – – Third U.S. Pa...

--News Direct-- Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update. Dr Vitt starts by describing the quarter as a "very eventful and positive quarter for us, dominated by a k...

2023-11-14 10:53:04 ET Immunic, Inc. (IMUX) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Dr. Daniel Vitt - CEO and President Glenn Whaley - CFO Conference Call Participants...

2023-11-14 06:30:08 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic For fu...

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire – Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overal...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

2023-11-13 13:12:56 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic Histor...